Navigation Links
EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Date:5/13/2008

ROCKVILLE, Md., May 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company overview at the Rodman and Renshaw 5th Annual Global Healthcare Conference, to be held at the Le Meridien Beach Plaza Hotel in Monte Carlo, May 19-20, 2008. Mr. Burns' presentation is scheduled for Monday, May 19, 2008 at 10:25 a.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

As previously mentioned, Mr. Burns' live presentation will be web cast and will serve as the Company's first quarter 2008 update. The presentation can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

CONTACT:

Ginny Dunn

Associate Director

Corporate Communications &Investor Relations

EntreMed, Inc.

240-864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. EntreMed Reports First Quarter 2008 Financial Results
2. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
3. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
4. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
5. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
6. EntreMed Reports Third Quarter 2007 Financial Results
7. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
8. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
9. EntreMed to Present at the Bio 2007 Investor Forum
10. EntreMed Receives Deloitte Technology Fast 50 Award
11. Emphasys Medical to Present VENT Clinical Trial Data at ATS 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology: